What are the latest evidence‑based guidelines for managing persistent shock of unknown origin?

Management of Persistent Shock from Undetermined Source

For ongoing shock of unknown etiology, immediately initiate aggressive fluid resuscitation with crystalloids (minimum 30 mL/kg) while simultaneously starting norepinephrine as first-line vasopressor to target MAP ≥65 mmHg, and urgently pursue diagnostic workup to identify the shock source. 1, 2

Initial Hemodynamic Stabilization

Fluid Resuscitation Strategy

• Begin with crystalloids as the primary resuscitation fluid (strong recommendation) 1

  • Administer at least 30 mL/kg as initial fluid challenge
  • Either balanced crystalloids or normal saline are acceptable
  • Consider adding albumin if substantial crystalloid volumes are required
  • Avoid hydroxyethyl starches entirely (strong recommendation against use) 1

• Use fluid challenge technique: Continue fluid administration only as long as hemodynamic parameters improve 1, 2

  • Monitor dynamic variables (pulse pressure variation, stroke volume variation) or static variables (arterial pressure, heart rate)
  • Reassess fluid responsiveness after initial resuscitation before giving additional fluids 2
  • Approximately 50% of patients will be fluid non-responders after initial resuscitation; continuing fluids in these patients risks harm without benefit

Vasopressor Management

Norepinephrine is the mandatory first-choice vasopressor (strong recommendation, Grade 1B) 1

Escalation algorithm when MAP target not achieved:

1. Second-line options (add to norepinephrine):

   • Vasopressin 0.03 units/min (to raise MAP or decrease norepinephrine dose) 1
   • OR epinephrine (if additional agent needed) 1

2. Dopamine: Reserve ONLY for highly selected patients with:

   • Low risk of tachyarrhythmias AND
   • Absolute or relative bradycardia 1
   • Never use low-dose dopamine for renal protection (strong recommendation against, Grade 1A) 1

3. Phenylephrine: Use ONLY in these specific circumstances:

   • Norepinephrine causes serious arrhythmias, OR
   • Cardiac output confirmed high with persistently low blood pressure, OR
   • Salvage therapy when all other agents fail 1

4. High-dose vasopressin (>0.03-0.04 units/min): Reserve for salvage therapy only 1

Inotropic Support

Add dobutamine (up to 20 μg/kg/min) when persistent hypoperfusion exists despite adequate fluid loading and vasopressor use 1

• Titrate to endpoints reflecting tissue perfusion
• Reduce or discontinue if worsening hypotension or arrhythmias develop

Monitoring Requirements

Hemodynamic Monitoring

• Place arterial catheter as soon as practical in all patients requiring vasopressors 1
• Target MAP ≥65 mmHg initially (Grade 1C) 1

Assessing Risk of Fluid Overload

Monitor these parameters to evaluate harm from continued fluid administration 2:

• Intravascular filling pressures
• Intra-abdominal pressure
• Extravascular lung water (EVLW)
• Pulmonary vascular permeability index
• VExUS (venous excess ultrasound) grading
• PaO₂/FiO₂ ratio
• Lung ultrasound score

Even in fluid-responsive patients, titrate fluids carefully when elevated filling pressures or extravascular lung water present 2

Diagnostic Workup While Resuscitating

Urgent Source Identification

Identify or exclude anatomic infection source requiring source control as rapidly as possible 1

• Implement required interventions as soon as medically and logistically practical
• Use least physiologically invasive effective intervention (e.g., percutaneous vs. surgical drainage)
• Remove intravascular access devices promptly if potential source after establishing alternative access 1

Tissue Perfusion Assessment

Evaluate effectiveness of resuscitation using:

• Capillary refill time (CRT)
• Skin mottling
• SpO₂
• pCO₂-derived variables
• Lactate levels 2

Adjunctive Therapies

Corticosteroids

Do NOT use IV hydrocortisone if adequate fluid resuscitation and vasopressor therapy restore hemodynamic stability 1

If hemodynamic stability NOT achievable:

• Consider hydrocortisone 200 mg/day (Grade 2C) 1
• Use continuous infusion (Grade 2D)
• Taper when vasopressors no longer required
• Do NOT use ACTH stimulation test to identify candidates 1

Blood Product Management

Transfuse RBCs only when hemoglobin <7.0 g/dL once tissue hypoperfusion resolved, targeting 7.0-9.0 g/dL (Grade 1B) 1

Exceptions requiring higher thresholds:

• Myocardial ischemia
• Severe hypoxemia
• Acute hemorrhage
• Ischemic heart disease

Do NOT use:

• Fresh frozen plasma to correct laboratory abnormalities without bleeding 1
• Antithrombin for treatment 1
• Erythropoietin for sepsis-associated anemia 1

Critical Pitfalls to Avoid

1. Never delay vasopressors waiting for fluid resuscitation completion - early vasopressor use prevents hypervolemia and improves outcomes 3

2. Do not continue fluids in non-responders - reassess responsiveness frequently; approximately 80% of already-resuscitated septic shock patients are fluid non-responders 2

3. Avoid using dopamine as first-line agent - associated with increased arrhythmias compared to norepinephrine 1

4. Do not use static preload measurements alone to predict fluid responsiveness 4

5. Hypotension is NOT required to define shock - inadequate tissue perfusion on physical examination is sufficient 4

Reassessment Strategy

Perform frequent reassessment of response to treatment 2

• Hemodynamic instability may recur over time
• Reassess fluid responsiveness whenever considering additional fluid administration
• Only 50% of initial fluid responders remain responsive 30 minutes after bolus infusion

The 2017 Surviving Sepsis Campaign guidelines [1-1] remain the primary evidence base, recently reinforced by 2025 ESICM circulatory shock guidelines 2 emphasizing early vasopressor use and judicious fluid administration based on responsiveness assessment rather than fixed protocols.